Русский
Safety of tadalafil in patients with cardiovascular comorbidities
DOI: https://dx.doi.org/10.18565/urology.2019.1.119-124
I.L. Nikitina, G.G. Gaysina, Sh.N. Galimov, K.V. Bulygin, E.F. Galimova, V.N. Pavlov
1) Bashkir State Medical University, Ufa, Russia; 2) I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 3) M.V. Lomonosov Moscow State University, Moscow, Russia
Tadalafil is a drug from the phosphodiesterase-5 inhibitors (PDE-5) group, which is used to treat erectile dysfunction (ED), lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) and ED with LUTS in patients with BPH. The efficacy and safety of tadalafil were reviewed. The focus was on cardiovascular safety of tadalafil due to frequent cardiovascular comorbidities in patients with ED. We concluded that tadalafil is well tolerated and safe in patients with cardiovascular comorbidities and, in addition, has a beneficial effect on the cardiovascular system.
Keywords: cardiovascular safety, phosphodiesterase-5 inhibitors, erectile dysfunction, tadalafil, cardiovascular pathology
About the Autors
Corresponding author: I.L. Nikitina – Ph.D., professor, Department of pharmacology with a course of clinical pharmacology, Bashkir State Medical University, Ufa, Russia; e-mail: irennixleo@gmail.com
Similar Articles
